- Home
- CANF vs DAKT Comparison
CANF vs DAKT Comparison
Compare CANF & DAKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- DAKT
- Stock Information
- Founded
- CANF 1994
- DAKT 1968
- Country
- CANF Israel
- DAKT United States
- Employees
- CANF N/A
- DAKT N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- DAKT Office Equipment/Supplies/Services
- Sector
- CANF Health Care
- DAKT Industrials
- Exchange
- CANF Nasdaq
- DAKT Nasdaq
- Market Cap
- CANF 7.9M
- DAKT N/A
- IPO Year
- CANF N/A
- DAKT 1994
- Fundamental
- Price
- CANF $1.11
- DAKT $14.02
- Analyst Decision
- CANF Strong Buy
- DAKT Strong Buy
- Analyst Count
- CANF 2
- DAKT 1
- Target Price
- CANF $14.00
- DAKT $26.00
- AVG Volume (30 Days)
- CANF 450.6K
- DAKT 208.5K
- Earning Date
- CANF 05-20-2025
- DAKT 06-25-2025
- Dividend Yield
- CANF N/A
- DAKT N/A
- EPS Growth
- CANF N/A
- DAKT N/A
- EPS
- CANF N/A
- DAKT 0.04
- Revenue
- CANF $674,000.00
- DAKT $799,806,000.00
- Revenue This Year
- CANF $461.72
- DAKT N/A
- Revenue Next Year
- CANF N/A
- DAKT $4.86
- P/E Ratio
- CANF N/A
- DAKT $359.83
- Revenue Growth
- CANF N/A
- DAKT N/A
- 52 Week Low
- CANF $1.02
- DAKT $10.24
- 52 Week High
- CANF $4.69
- DAKT $19.89
- Technical
- Relative Strength Index (RSI)
- CANF 40.05
- DAKT 67.76
- Support Level
- CANF $1.02
- DAKT $12.37
- Resistance Level
- CANF $1.20
- DAKT $12.80
- Average True Range (ATR)
- CANF 0.06
- DAKT 0.38
- MACD
- CANF 0.01
- DAKT 0.20
- Stochastic Oscillator
- CANF 40.91
- DAKT 93.01
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).